USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Rainbow Medical Ltd.

USPTO PatentsView assignee record - 59 granted patents across 8 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

20.1

Avg claims per patent

+19%

5-year grant velocity

The verdict

According to USPTO PatentsView, Rainbow ranks #5,789 of 50,000 tracked US assignees by granted-patent volume, with 59 patents across 8 technology areas.

#5,789
of 50,000 US assignees by volume: Top 40%
by Innovation Score (38.8/100): 20.1
avg claims per patent: +19%
grant velocity, last 5 yrs

Portfolio overview

Rainbow Medical Ltd. has been granted 59 US utility patents between 2015 and 2023, placing Rainbow Medical Ltd. at #5,789 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.1 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a Foreign Corporation, Rainbow Medical Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Rainbow sits between Otsuka Pharmaceutical Factory, Inc. (59 patents, rank #5,785) and Si-bone Inc. (59 patents, rank #5,793) - the closest US assignees by grant volume. The composite Innovation Score of 38.8/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 32 grants, compared with 27 in the 2015–2019 window, a +19% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Rainbow Medical Ltd.'s 20.1 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 8 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Otsuka Pharmaceut…

59
Pum-tech Korea

59
Plansee SE

59
Qingdao PICO Tech…

59
Rebellion Photoni…

59
Revision Military…

59
Shanghai IC R&D C…

59
Si-bone

59
Rainbow Medical ◀

59

What this shows Rainbow holds 59 patents at rank #5,789, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Rainbow

By rank, the assignees closest to #5,789 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Rainbow's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Rainbow, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (39 here).

Metso Minerals, Inc. 39 Jahwa Electronics Co., Ltd. 39 Cradlepoint, Inc. 39 Permobil AB 39

Similar claim depth

Nearest assignees by average claims per patent (20.1 here).

Applied Micro Circuits Corporation 20.1 avg Cardinal IG Company 20.1 avg Tactotek OY 20.1 avg VID Scale, Inc. 20.1 avg

Rainbow's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 40% higher than 60% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Rainbow Medical Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	6.8%
2016	3	5.1%
2017	10	16.9%
2018	3	5.1%
2019	7	11.9%
2020	11	18.6%
2021	10	16.9%
2022	10	16.9%
2023	1	1.7%

Which technologies does Rainbow Medical Ltd. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 36

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 15

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 12

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 11

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 2

G02C - SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES 1

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 1

H02J - CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY 1

Top 8 of 8 technology areas

Grant record at a glance

Portfolio Volume 59 grants

CPC subclasses 8

Avg. claims / grant 20.1

Velocity +19%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#5,789

of 50,000 tracked assignees

Innovation Score

38.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Rainbow Medical Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Rainbow Medical Ltd. ranks #5,789 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Rainbow Medical Ltd. hold?

Rainbow Medical Ltd. holds 59 US utility patents granted between 2015 and 2023, spanning 8 technology areas.

What is Rainbow Medical Ltd.'s Innovation Score?

Rainbow Medical Ltd. has an Innovation Score of 38.8 out of 100 (top 40% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Rainbow Medical Ltd. focus on?

Rainbow Medical Ltd.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 36 patents. Grants appear in 8 CPC subclasses total.

Is Rainbow Medical Ltd.'s patent grant rate increasing or decreasing?

Rainbow Medical Ltd.'s recent grant velocity is +19% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Rainbow Medical Ltd.'s patents?

Rainbow Medical Ltd.'s patents average 20.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Rainbow Medical Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Rainbow's 59 grants land it in the top 40% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Rainbow ranks #5,789 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61N - see who else leads that technology area. A61N leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.